Balance Sheet
Cash Flow Statement
AmortizationAmortization of GoodwillAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Legend Biotech (LEGN) Amortization (2020 - 2025)

Historic Amortization for Legend Biotech (LEGN) over the last 6 years, with Q3 2025 value amounting to -$20.8 million.

  • Legend Biotech's Amortization fell 112796.44% to -$20.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$141.6 million, marking a year-over-year decrease of 709817.19%. This contributed to the annual value of -$402.5 million for FY2022, which is 1136.93% down from last year.
  • Per Legend Biotech's latest filing, its Amortization stood at -$20.8 million for Q3 2025, which was down 112796.44% from $3.5 million recorded in Q2 2025.
  • Legend Biotech's Amortization's 5-year high stood at $3.5 million during Q2 2025, with a 5-year trough of -$402.5 million in Q4 2022.
  • Over the past 5 years, Legend Biotech's median Amortization value was -$64.4 million (recorded in 2022), while the average stood at -$91.5 million.
  • As far as peak fluctuations go, Legend Biotech's Amortization soared by 10210.16% in 2023, and later plummeted by 112796.44% in 2025.
  • Legend Biotech's Amortization (Quarter) stood at -$361.4 million in 2021, then decreased by 11.37% to -$402.5 million in 2022, then surged by 100.5% to $2.0 million in 2023, then rose by 0.05% to $2.0 million in 2024, then plummeted by 1127.96% to -$20.8 million in 2025.
  • Its Amortization was -$20.8 million in Q3 2025, compared to $3.5 million in Q2 2025 and -$32.7 million in Q1 2025.